Pathogenic germline variants in BRCA1/2 are present in 12%-15% of patients with high-grade nonmucinous ovarian cancer (HGNMOC),8,10 the highest prevalence of any malignancy and therefore representing a sentinel cancer for BRCA1/2 carriers. This evidence concerns the gene BRCA1 and cancer.